Back to top

Analyst Blog

Recently, DaVita Inc. (DVA - Analyst Report) revealed that it received intimation from the United States Attorney's Office for St. Louis regarding lack of any action against the company following the completion of a joint civil and criminal investigation. The company will not have to face any charges, make any payments or change any policy as an outcome of the investigation.

The St. Louis Attorney's Office had commenced the investigation against DaVita in March 2005, regarding various matters such as financial relationships with physicians, joint ventures, and administration and billing of Amgen Inc.’s (AMGN) Epogen, which is used for increasing the red blood cell count in chronic kidney disease patients on dialysis.

Consequently, the Attorney’s Office had issued a subpoena and requested innumerable documents from the company. DaVita provided complete cooperation to the government and submitted all necessary documents. The company maintained that it respected the government’s right to investigate into issues related to regulatory compliance. However, DaVita also upheld that it has a history of compliance.

The absence of any action against the company indicates that the Attorney’s Office did not find any irregularity during the investigation. This is positive news for DaVita, which agreed to pay $55 million to settle a lawsuit accusing it of overusing Epogen in July this year.

However, while announcing the settlement, the company maintained its stand that the charge was baseless and physicians employed by it were not guilty. Nevertheless, DaVita agreed to the settlement as it considered that to be the most beneficial option for its shareholders.

DaVita, which competes with HealthSouth Corporation (HLS), currently retains a Zacks #2 Rank, implying a short-term Buy rating. We maintain a long-term Neutral recommendation on the stock.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%